# Curium

Source: https://onco.cc/companies/curium/  
OnCo record `curium` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.

## Summary

Curium is a Paris-based private radiopharmaceutical group, one of the largest in nuclear medicine, supplying SPECT and PET isotopes and generators and developing 177Lu-PSMA-I&T as a competitor to Pluvicto in prostate cancer. Its ECLIPSE phase 3 trial of 177Lu-PSMA-I&T met its radiographic progression-free survival endpoint in taxane-naive metastatic castration-resistant prostate cancer, a Japanese registrational trial with PeptiDream and PDRadiopharma enrolled its first patient in February 2026, and the regulatory submission plan is under discussion with the FDA. In September 2026 the FDA approved Bexlutry, Curium's lutetium-177 dotatate, for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours. On 3 August 2026 Curium agreed to acquire Lantheus for 102.50 dollars a share in cash plus contingent value rights of up to 12 dollars a share, a total of up to about 8.0 billion dollars; the US Federal Trade Commission asked for more information on 21 October 2026, and the companies expect to close in the first half of 2027. OnCo links it to DOTATATE imaging agents, samarium-153 lexidronam, radionuclide generators and the therapeutic isotope supply chain. Whether a second lutetium PSMA agent can differentiate on supply and price rather than efficacy is the open question. The manufacturing cost of radioactive medicines is the bottleneck it bears on.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Paris
- Type: radiopharma
- Website: https://www.curiumpharma.com

## Notes

- Checked 29 October 2026. Lantheus deal terms are from the joint release filed by Lantheus with the SEC on 3 August 2026; the FTC second request and the first-half 2027 closing expectation are from Lantheus's 8-K of 22 October 2026. The deal had not closed at the time of checking. Bexlutry approval is from Curium's release dated 14 September 2026. Curium also announced the acquisition of Abscint, a PET radiodiagnostics company, in August 2026; its terms were not checked.

## Sources

- Official website: https://www.curiumpharma.com
- Curium to merge with Lantheus (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1521036/000119312526329622/d148563dex991.htm
- FTC second request on the Lantheus merger, Form 8-K (SEC): https://www.sec.gov/Archives/edgar/data/1521036/000119312526428324/d19181d8k.htm
- FDA approval of Bexlutry: https://www.curiumpharma.com/fda-approval-bexlutry/

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- drugs: [177Lu-PSMA-I&T](https://onco.cc/drugs/lu177-psma-it/), [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://onco.cc/drugs/ga68-dotatate/), [Piflufolastat F-18 / Pylarify TruVu](https://onco.cc/drugs/pylarify/), [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/)
- companies: [Lantheus](https://onco.cc/companies/lantheus/)
- trials: [Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer](https://onco.cc/trials/nct06235151/), [ECLIPSE](https://onco.cc/trials/eclipse-psma/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- technologies: [Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)](https://onco.cc/technologies/cyclotron-isotope-production/), [Radionuclide generators and cold kits](https://onco.cc/technologies/radionuclide-generators-kits/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/), [Radiopharmacy and cyclotron networks](https://onco.cc/technologies/radiopharmacy-network/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://onco.cc/technologies/research-reactor-isotope-production/), [Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)](https://onco.cc/technologies/therapy-isotope-supply-chain/)

---
JSON: https://onco.cc/api/v1/entities/curium.json